natgillin/translations-raw huggingface dataset:
Bortezomib Sun is a ‘generic medicine’.
Zdravilo Bortezomib Sun je „generično zdravilo“.
Bortezomib SUN is administered via intravenous or subcutaneous injection in combination with oral melphalan and oral prednisone as shown in Table 2.
Zdravilo Bortezomib SUN se daje intravensko ali subkutano v kombinaciji s peroralnim melfalanom in prednizonom, kot je prikazano v preglednici 2.
Bortezomib SUN is available for intravenous or subcutaneous administration.
Zdravilo Bortezomib SUN je namenjeno za intravensko ali subkutano uporabo.
Bortezomib Sun is either used on its own in these patients or in combination with pegylated liposomal doxorubicin or dexamethasone; previously untreated adults who cannot have high-dose chemotherapy with blood stem-cell transplantation.
Zdravilo Bortezomib Sun se pri teh bolnikih uporablja samostojno ali v kombinaciji s pegiliranim liposomalnim doksorubicinom ali deksametazonom; predhodno nezdravljenih odraslih, ki jih ni mogoče zdraviti s kemoterapijo z velikimi odmerki s sočasno presaditvijo krvotvornih matičnih celic.
Bortezomib SUN is for intravenous or subcutaneous use.
Zdravilo Bortezomib SUN je namenjen za intravensko ali subkutano uporabo.
Bortezomib SUN is given intravenously or subcutaneously on days 1, 4, 8 and 11, followed by a ‘rest period’ without treatment.
Zdravilo Bortezomib SUN boste prejeli intravensko na 1., 4., 8. in 11. dan, temu pa bo sledil premor brez zdravljenja.
Bortezomib SUN is used for the treatment of:
Zdravilo Bortezomib SUN se uporablja za zdravljenje:
Bortezomib SUN might cause tiredness, dizziness, fainting, or blurred vision.
Zdravilo Bortezomib SUN lahko povzroči utrujenost, omotičnost, omedlevico ali zamegljen vid.
Bortezomib SUN must be reconstituted by a healthcare professional.
Zdravilo Bortezomib SUN mora rekonstituirati zdravstveno osebje.
Bortezomib SUN reconstituted solution is administered as a 3-5 second bolus intravenous injection through a peripheral or central intravenous catheter followed by a flush with sodium chloride 9 mg/ml (0.9%) solution for injection.
Rekonstituirano raztopino zdravila Bortezomib SUN dajte naenkrat v obliki 3-5 sekund trajajoče bolusne intravenske injekcije prek perifernega ali osrednjega intravenskega katetra, čemur naj sledi izpiranje katetra z 9 mg/ml (0,9 %) raztopino natrijevega klorida za injiciranje.
Bortezomib SUN reconstituted solution is administered subcutaneously through the thighs (right or left) or abdomen (right or left).
Rekonstituirano raztopino zdravila Bortezomib SUN injiciramo subkutano v stegno (desno ali levo) ali trebuh (desno ali levo).
Bortezomib SUN should not be used in children and adolescents because it is not known how the medicine will affect them.
Zdravilo Bortezomib SUN se pri otrocih in mladostnikih ne sme uporabljati, ker njegovega vpliva nanje ne poznamo.
Bortezomib SUN therapy should be withheld
Ne aplicirajte zdravilom Bortezomib SUN.
Bortezomib treatment must be withheld at the onset of any ≥ Grade 3 bortezomib -related non-haematological toxicities (excluding neuropathy) or ≥ Grade 3 haematological toxicities (see also section 4.4).
Zdravljenje z bortezomibom je treba prekiniti ob pojavu katere koli z uporabo z bortezomibom povezane ne-hematološke toksičnosti stopnje ≥ 3 (razen nevropatije) ali hematološke toksičnosti stopnje ≥ 3 (glejte tudi poglavje 4.4).
Bortezomib was administered only in Blocks 1 and 2 to avoid potential overlapping toxicities with coadministered drugs in Block 3.
Bolniki so prejeli zdravilo bortezomib le v 1. in 2. sklopu zdravljenja, da so izognili prekrivanju toksičnih učinkov z drugimi, sočasno danimi zdravili v
Bortezomib: AUC: ↑ 1.4-fold
Bortezomib: AUC: ↑ 1,4-krat
Bosentan
flurazepam
bosentan (another treatment for pulmonary aterial hypertension)
bosentan (drugo zdravljenje pljučne arterijske hipertenzije),
Bosentan (n=80)
Bosentan (n = 80)
Bosentan (to treat high blood pressure in the pulmonary circulation)
bosentan (za zdravljenje visokega krvnega tlaka v pljučnem krvnem obtoku)
bosentan (to treat high blood pressure or ulcers of the fingers)
bosentan (za zdravljenje visokega krvnega tlaka ali razjed na prstih)
bosentan (used to treat high blood pressure in the lungs) valsartan, olmesartan (used to treat high blood pressure)
bosentan (za zdravljenje visokega krvnega tlaka v pljučih) valsartan, olmesartan (za zdravljenje visokega krvnega tlaka).
bosentan (used to treat pulmonary artery hypertension)
bosentana (zdravilo za zdravljenje pljučne arterijske hipertenzije),
Bosentan Co-administration of bosentan and ritonavir may increase steady state bosentan maximum concentr ations (Cmax) and area under the curve (AUC).
Sočasna uporaba bosentana in ritonavirja lahko poveča maksimalno koncentracijo bosentana v stanju dinamičnega ravnovesja in površino pod krivuljo (AUC).
Bosentan competes with the binding of ET-1 and other ET peptides to both ETA and ETB receptors, with a slightly higher affinity for ETA receptors (Ki = 4.1–43 nanomolar) than for ETB receptors (Ki = 38-730 nanomolar).
Bosentan tekmuje z vezavo ET-1 in drugih peptidov ET na receptorje ETA in ETB, z malo večjo afiniteto za receptorje ETA (Ki = 4,1–43 nanomolarna) kot za receptorje ETB (Ki = 38-730 nanomolarna).
Bosentan competes with the binding of ET-1 and other ET peptides to both ETA and ETB receptors, with a slightly higher affinity for ETA receptors (Ki = 4.1–43 nanomolar) than for ETB receptors (Ki = 38–
Bosentan tekmuje z vezavo ET-1 in drugih peptidov ET na receptorje ETA in ETB, z malo večjo afiniteto za receptorje ETA (Ki = 4,1–43 nanomolarna) kot za receptorje ETB (Ki = 38-730 nanomolarna).
Bosentan competes with the binding of ET-1 and other ET peptides to both ETA and ETB receptors, with a slightly higher affinity for ETA receptors (Ki = 4.1–43 nanomolar) than for ETB receptors (Ki = 38–730 nanomolar).
Bosentan tekmuje z vezavo ET-1 in drugih peptidov ET na receptorje ETA in ETB, z malo večjo afiniteto za receptorje ETA (Ki = 4,1–43 nanomolarna)) kot za receptorje ETB (Ki = 38-730 nanomolarna).
Bosentan film-coated tablets were evaluated in an open-label uncontrolled study in 19 paediatric patients with pulmonary arterial hypertension aged 3 to 15 years.
Filmsko obložene tablete z bosentanom so ocenili v nenadzorovani študiji z znanim zdravilom pri 19 pediatričnih bolnikih s pljučno arterijsko hipertenzijo , starih od 3 do 15 let.
Bosentan film-coated tablets were evaluated in an open-label uncontrolled study in 19 paediatric patients with pulmonary arterial hypertension aged 3to 15 years.
Filmsko obložene tablete z bosentanom so ocenili v nenadzorovani študiji z znanim zdravilom pri 19 pediatričnih bolnikih s pljučno arterijsko hipertenzijo , starih od 3 do 15 let.
bosentan for pulmonary arterial hypertension
bosentan za pljučno arterijsko hipertenzijo,
Bosentan has been administered as a single dose of up to 2400 mg to healthy subjects and up to 2000 mg/day for 2 months in patients with a disease other than pulmonary hypertension.
Bosentan so dajali v enkratnem odmerku do 2400 mg zdravim osebam in do 2000 mg na dan 2 meseca bolnikom, ki niso imeli pljučne hipertenzije pač pa drugo bolezen.
Bosentan is a dual endothelin receptor antagonist (ERA) with affinity for both endothelin A and B (ETA and ETB) receptors.
Bosentan je dvojni antagonist endotelinskih receptorjev (ERA – Endothelin Receptor Antagonist) z afiniteto za endotelinske receptorje A in B (ETA in ETB).
Bosentan was added to patients’ current therapy, which could include a combination of anticoagulants, vasodilators (e.g., calcium channel blockers), diuretics, oxygen and digoxin, but not epoprostenol.
Bosentan so dodali k tedanji terapiji bolnikov, ki je lahko vključevala kombinacijo antikoagulantov, vazodilatatorjev (denimo, zaviralcev kalcijevih kanalčkov), diuretike, kisik in digoksin, ne pa epoprostenola.
bosentan – used to treat pulmonary artery hypertension
bosentan – uporablja se za zdravljenje pljučne arterijske hipertenzije,
bosentan, a medicine used to treat pulmonary arterial hypertension
bosentan, zdravilo, ki se uporablja za zdravljenje pljučne arterijske hipertenzije
bosentan, a medicine used to treat pulmonary arterial hypertension
bosentan; zdravilo, ki se uporablja za zdravljenje pljučne arterijske hipertenzije
Bosentan, riociguat (used for pulmonary arterial hypertension) as Norvir may increase the blood levels of this medicine
Bosentan, riociguat (za pljučno arterijsko hipertenzijo), ker lahko zdravilo Norvir poveča koncentracijo tega zdravila v krvi.
Bosentan, riociguat (used for pulmonary arterial hypertension) as Norvir may increase the blood levels of this medicine.
Bosentan, riociguat (za pljučno arterijsko hipertenzijo), ker lahko zdravilo Norvir poveča koncentracijo tega zdravila v krvi.
bosentan, used to treat pulmonary arterial hypertension
bosentan, uporablja se za zdravljenje pljučne arterijske hipertenzije
bosentan.
Bosentan
Bosentan: AUC: ↑ 2-fold Cmax: ↑ 2-fold
AUC: ↑ 2-krat Cmax: ↑ 2-krat
Bosulif 100 mg are yellow, oval biconvex, film-coated tablets debossed with “Pfizer” on one side and “100” on the other side.
Zdravilo Bosulif 100 mg so rumene, ovalne, bikonveksne filmsko obložene tablete, z oznako “Pfizer” na eni strani in “100” na drugi strani.
Bosulif 100 mg film-coated tablets
Bosulif 100 mg filmsko obložene tablete
Bosulif 100 mg film-coated tablets Bosulif 500 mg film-coated tablets
Bosulif 100 mg filmsko obložene tablete Bosulif 500 mg filmsko obložene tablete
Bosulif 100 mg film-coated tablets Bosulif 500 mg film-coated tablets bosutinib
Bosulif 100 mg filmsko obložene tablete Bosulif 500 mg filmsko obložene tablete bosutinib
Bosulif 100 mg film-coated tablets Bosutinib
Bosulif 100 mg filmsko obložene tablete bosutinib
Bosulif 100 mg is available in blisters containing either 14 or 15 tablets.
Zdravilo Bosulif 100 mg je na voljo v pretisnih omotih, ki vsebujejo ali 14 ali 15 tablet.
Bosulif 500 mg are red, oval biconvex, film-coated tablets debossed with “Pfizer” on one side and “500” on the other side.
Zdravilo Bosulif 500 mg so rdeče, ovalne, bikonveksne filmsko obložene tablete, z oznako “Pfizer” na eni strani in “500” na drugi strani.
Bosulif 500 mg film-coated tablets
Bosulif 500 mg filmsko obložene tablete
Bosulif 500 mg film-coated tablets
Bosulif 500 mg filmsko obložene tablete EU/1/13/818/003
Bosulif 500 mg film-coated tablets Bosutinib
Bosulif 500 mg filmsko obložene tablete bosutinib
Bosulif 500 mg is available in blisters containing either 14 or 15 tablets.
Zdravilo Bosulif 500 mg je na voljo v pretisnih omotih, ki vsebujejo ali 14 ali 15 tablet.
Bosulif contains the active substance bosutinib.
Zdravilo Bosulif vsebuje zdravilno učinkovino bosutinib.
Bosulif could harm an unborn baby, so it should not be used unless considered necessary during pregnancy.
Zdravilo Bosulif lahko škoduje nerojenemu otroku, zato se ga med nosečnostjo ne sme uporabljati, razen če ni to potrebno.
Bosulif has been given ‘conditional approval’.
Zdravilo Bosulif je pridobilo „pogojno dovoljenje za promet‟.
Bosulif has no or negligible influence on the ability to drive and use machines.
Zdravilo Bosulif nima vpliva ali ima zanemarljiv vpliv na sposobnost vožnje in upravljanja s stroji.
Bosulif is an anticancer medicine that contains the active substance bosutinib.
Bosulif je zdravilo za zdravljenje raka, ki vsebuje zdravilno učinkovino bosutinib.
Bosulif is available as tablets (100 mg and 500 mg).
Zdravilo Bosulif je na voljo v obliki tablet (100 mg in 500 mg).
Bosulif is indicated for the treatment of adult patients with chronic phase (CP), accelerated phase (AP), and blast phase (BP) Philadelphia chromosome positive chronic myelogenous leukaemia (Ph+ CML) previously treated with one or more tyrosine kinase inhibitor(s) and for whom imatinib, nilotinib and dasatinib are not considered appropriate treatment options.
Zdravilo Bosulif je indicirano za zdravljenje odraslih bolnikov v kronični fazi, pospešeni fazi in blastni fazi kronične mieloične levkemije s prisotnim kromosomom Philadelphia (Ph+ KML), ki so bili predhodno zdravljeni z enim ali več zaviralci tirozinske kinaze in pri katerih zdravljenje z imatinibom, nilotinibom ali dasatinibom ni primerno.
Bosulif is not recommended for use during pregnancy, or in women of childbearing potential not using contraception.
Zdravila Bosulif ni priporočljivo uporabljati med nosečnostjo ali pri ženskah v rodni dobi, ki ne uporabljajo kontracepcije.
Bosulif is used in patients who are ‘Philadelphia-chromosome positive’ (Ph+).
Zdravilo Bosulif se uporablja pri bolnikih, pri katerih je prisoten kromosom Philadelphia (Ph+).
Bosulif may predispose patients to bacterial, fungal, viral or protozoan infections.
Zdravilo Bosulif lahko poveča nagnjenost bolnikov k bakterijskim, glivičnim, virusnim ali protozojskim okužbam.
Bosulif must not be used in patients with reduced liver function.
Zdravilo Bosulif se ne sme uporabljati pri bolnikih z motnjami delovanja jeter.
Bosulif should be administered with caution to patients who have a history of or predisposition for QTc prolongation, who have uncontrolled or significant cardiac disease including recent myocardial infarction, congestive heart failure, unstable angina or clinically significant bradycardia, or who are taking medicinal products that are known to prolong the QT interval (e.g., anti-arrhythmic medicinal products and other substances that may prolong QT [section 4.5]).
Zdravilo Bosulif je treba uporabljati previdno pri bolnikih z anamnezo ali predispozicijo za podaljšanje intervala QTc, pri bolnikih z nenadzorovano ali klinično pomembno srčno boleznijo (vključno z nedavnim miokardnim infarktom, kongestivnim srčnim popuščanjem, nestabilno angino pektoris ali klinično pomembno bradikardijo) ali pri bolnikih, ki jemljejo zdravila, za katera je znano, da podaljšujejo interval QT (npr. antiaritmiki in druge učinkovine, ki lahko podaljšajo interval QT [poglavje 4.5]).
Bosulif treatment was effective in patients with an unmet medical need: 18 out of 36 patients with chronic phase CML had a ‘major cytogenetic response’, while 7 out of the 16 patients with advanced (accelerated or blast phase) CML also had a sufficient response based on other measurements.
Zdravljenje z zdravilom Bosulif je bilo učinkovito pri bolnikih, katerih zdravstvene potrebe večinoma niso bile izpolnjene: 18 od 36 bolnikov s kronično mieloično levkemijo v kronični fazi je imelo „pomemben citogenični odziv‟, medtem ko je imelo 7 od 16 bolnikov z napredovalo kronično mieloično levkemijo (v pospešeni ali blastni fazi) prav tako zadovoljiv odziv na podlagi drugih meritev.
Bosulif was investigated in one main study involving 570 patients with Ph+ CML who had previously been treated with at least one tyrosine kinase inhibitor.
Zdravilo Bosulif so proučevali v eni glavni študiji, ki je vključevala 570 bolnikov s KML Ph+, ki so bili v preteklosti zdravljeni z vsaj enim zaviralcem tirozin kinaze.
Bosulif was not compared with another treatment.
Zdravila Bosulif niso primerjali z drugimi zdravljenji.
Bosulif with food and drink
Zdravilo Bosulif skupaj s hrano in pijačo
Bosutinib activity in vitro in hERG assays suggested a potential for prolongation of cardiac ventricular repolarization (QT interval).
Aktivnost bosutiniba pri hERG testih in vitro kaže na možnost podaljšanja repolarizacije srčnih ventriklov (intervala QT).
Bosutinib also inhibits receptor tyrosine kinases c-Fms, EphA and B receptors, Trk family kinases, Axl family kinases, Tec family kinases, some members of the ErbB family, the non-receptor tyrosine kinase Csk, serine/threonine kinases of the Ste20 family and two calmodulin-dependent protein kinases.
Bosutinib zavira tudi receptorske tirozinske kinaze c-Fms, receptorje EphA in EphB, kinaze iz družine Trk, kinaze iz družine Axl, kinaze iz družine Tec, nekatere člane družine ErbB, nereceptorske tirozinske kinaze Csk, serinske/treoninske kinaze iz družine Ste20 in dve proteinski kinazi, odvisni od kalmodulina.
Bosutinib belongs to a pharmacologic class of medicinal products known as kinase inhibitors.
Bosutinib sodi v farmakološko skupino zdravil, imenovanih zaviralci kinaze.
Bosutinib exhibits dose proportional increases in AUC and Cmax, over the dose range of 200 to 600 mg.
Bosutinib izkazuje od odmerka odvisno naraščanje AUC in Cmax v razponu odmerkov od 200 do 600 mg.
Bosutinib exposure was not increased in subjects with mild renal impairment.
Pri preiskovancih z blago okvaro ledvic se izpostavljenost bosutinibu ni povečala.
Bosutinib has been evaluated in safety pharmacology, repeated dose toxicity, genotoxicity, reproductive toxicity and photoxicity studies.
Zdravilo Bosulif so ocenjevali v študijah farmakološke varnosti, toksičnosti pri ponavljajočih odmerkih, genotoksičnosti, vpliva na sposobnost razmnoževanja in fototoksičnosti.
Bosutinib has demonstrated the ability to absorb light in the UV-B and UV-A range and is distributed into the skin and uveal tract of pigmented rats.
Bosutinib je pokazal sposobnost za absorpcijo svetlobe v UV-B in UV-A območju; porazdeli se v kožo in uvealni trakt pigmentiranih podgan.
Bosutinib inhibited 16 of 18 imatinib-resistant forms of Bcr-Abl expressed in murine myeloid cell lines.
Bosutinib je zaviral 16 od 18 oblik Bcr-Abl, odpornih na imatinib, izraženih v mieloidnih celičnih linijah glodalcev.
Bosutinib inhibits the abnormal Bcr-Abl kinase that promotes CML.
Bosutinib zavira nenormalno kinazo Bcr-Abl, ki pospešuje KML.
Bosutinib is also an inhibitor of Src family kinases including Src, Lyn and Hck; Bosutinib minimally inhibits PDGF receptor and c-Kit.
Bosutinib je tudi zaviralec kinaz iz družine Src, vključno s Src, Lyn, in Hck, minimalno pa zavira tudi receptor PDGF in c-Kit.
Bosutinib should be used with caution in patients who have or may develop prolongation of QT, including those patients taking anti-arrhythmic medicinal products such as amiodarone, disopyramide, procainamide, quinidine and sotalol or other medicinal products that may lead to QT prolongation such as chloroquine, halofantrine, clarithromycin, domperidone, haloperidol, methadone and moxifloxacin (see section 4.4).
Bosutinib je treba uporabljati previdno pri bolnikih, ki imajo podaljšan interval QT ali pa lahko pri njih do tega pride, vključno z bolniki, ki jemljejo antiaritmike, kot so amiodaron, dizopiramid, prokainamid, kinidin in sotalol, ali druga zdravila, ki lahko povzročijo podaljšanje intervala QT, kot so klorokin, halofantrin, klaritromicin, domperidon, haloperidol, metadon in moksifloksacin (glejte poglavje 4.4).
Bosutinib treatment reduced the size of CML tumours growing in nude mice and inhibited growth of murine myeloid tumours expressing imatinib-resistant forms of Bcr-Abl.
Zdravljenje z bosutinibom je zmanjšalo velikost KML tumorjev, ki so rasli na golih miših, ter pri glodalcih zaviralo rast mieloidnih tumorjev, ki so izražali na imatinib odporne oblike Bcr-Abl.
Bosutinib was highly bound to human plasma proteins in vitro (94%) and ex vivo in healthy subjects (96%), and binding was not concentration-dependent.
Bosutinib se je in vitro (94 %) ter ex vivo pri zdravih preiskovancih (96 %) v veliki meri vezal na človeške plazemske beljakovine; vezava ni bila odvisna od koncentracije.
Bosutinib was not carcinogenic in the 2-year rat carcinogenicity study.
V dveletni študiji kancerogenosti na podganah bosutinib ni bil kancerogen.
Both 60 mg twice daily and 90 mg twice daily regimens of ticagrelor in combination with ASA were superior to ASA alone in the prevention of atherothrombotic events (composite endpoint: CV
Shemi s ticagrelorjem 60 mg dvakrat na dan in 90 mg dvakrat na dan v kombinaciji z ASA sta bili za preprečevanje aterotrombotičnih dogodkov (sestavljeni opazovani dogodek: kardiovaskularna smrt, miokardni infarkt in možganska kap) superiorni nad samo ASA z doslednim terapevtskim učinkom med celotnim obdobjem študije.
Both abacavir and dolutegravir are associated with a risk for hypersensitivity reactions (HSR) (see section 4.8), and share some common features such as fever and/or rash with other symptoms indicating multi-organ involvement.
Tako abakavir kot dolutegravir povezujejo s tveganjem za pojav preobčutljivostnih reakcij (glejte poglavje 4.8), ki imajo nekatere skupne značilnosti, kot so povišana telesna temperatura in/ali
Both abacavir and lamivudine have been shown to inhibit replication of laboratory strains and clinical isolates of HIV in a number of cell types, including transformed T cell lines, monocyte/macrophage derived lines and primary cultures of activated peripheral blood lymphocytes (PBLs) and monocyte/macrophages.
Abakavir in lamivudin oba dokazano zavirata replikacijo laboratorijskih sevov in kliničnih izolatov HIV v številnih vrstah celic, vključno s transformiranimi linijami celic T, iz monocitov/makrofagov nastalimi linijami ter v primarnih kulturah aktiviranimi limfociti iz periferne krvi in monociti/makrofagi.
Both active substances have already been authorised in the European Union (EU), follitropin alfa as GONAL-f and lutropin alfa as Luveris.
Obe zdravilni učinkovini sta v Evropski uniji (EU) že odobreni, folitropin alfa kot zdravilo GONAL-f, lutropin alfa pa kot zdravilo Luveris.
Both active substances have been authorised in the European Union (EU) since the early 2000s: emtricitabine was authorised as Emtriva in 2003, and tenofovir disoproxil was authorised as Viread in 2002.
Obe zdravilni učinkovini imata dovoljenje za promet v Evropski uniji (EU) od začetka 21. stoletja: emtricitabin kot zdravilo Emtriva od leta 2003, tenofovir dizoproksil pa kot zdravilo Viread od leta 2002.
Both adverse reactions and laboratory values have been used.
Uporabljeni so neželeni učinki in laboratorijske vrednosti.
Both are anti– hypertensive medicines that have been available separately in the European Union (EU) since the mid- 1990s.
Obe učinkovini sta zdravili proti zvišanemu krvnemu tlaku, ki sta bili v Evropski uniji (EU) od sredine 90-ih let prejšnjega stoletja na voljo kot ločeni zdravili.
Both bioavailability and BMD gains are reduced when food or beverage is taken less than 60 minutes after ibandronic acid is ingested.
Če zaužijemo hrano ali pijačo, preden je minilo 60 minut od jemanja ibandronske kisline, se biološka uporabnost in porast MKG zmanjšata.
Both ceftazidime and avibactam penetrate into human bronchial epithelial lining fluid (ELF) to the same extent with concentrations around 30% of those in plasma.
Ceftazidim in avibaktam pri človeku oba prodirata v bronhialno epitelijsko tekočino v enaki meri in v njej dosežeta koncentracijo, ki znaša približno 30 % koncentracije v plazmi.
Both clomipramine and desmethylclomipramine contribute to the effects of Clomicalm: clomipramine is a potent and selective 5-HT reuptake inhibitor while desmethylclomipramine is a potent and selective noradrenaline reuptake inhibitor.
Klomipramin je učinkovit in selektiven zaviralec prevzema serotonina, desmetilklomipramin pa noradrenalina.
Both Cmax and AUC of buprenorphine increased with the increase in dose (in the range of 4-16 mg), although the increase was less than dose-proportional.
Vrednosti Cmax in AUC buprenorfina sta se povečali s povečanjem odmerka (v razponu od 4–16 mg), čeprav povečanje ni bilo odvisno od odmerka.
Both Cmax and AUC values are dose proportional.
Vrednosti Cmax in AUC sta sorazmerni odmerku.
Both components are mixed together just before your child receives the injection.
Tik preden bo vaš otrok prejel odmerek, bodo obe komponenti pomešali skupaj.
Both components of this medicinal product should be infused using a variable rate, infusion pump with a subcutaneous needle set that is at least 24 gauge with the ability to titrate flow up and down.
Komponenti tega zdravila je treba infundirati s spremenljivo hitrostjo, črpalko s subkutano iglo, ki je velikosti vsaj 24 in ima zmožnost titracije pretoka navzgor in navzdol.
Both CYP2C9 and CYP3A4 are involved in the metabolism of ospemifene.
Pri presnovi ospemifene sodelujeta tako CYP2C9 kot CYP3A4.
Both cytochromes P450-2D6 and 1A2 catalyse the formation of the two major metabolites glucuronide conjugate of 4-hydroxy duloxetine and sulfate conjugate of 5-hydroxy 6-methoxy duloxetine.
Oba citokroma, P450-2D6 in 1A2, katalizirata tvorbo dveh poglavitnih presnovkov glukuronidnega konjugata 4- hidroksi duloksetina in sulfatnega konjugata 5-hidroksi 6-metoksi duloksetina.